Skip to main content
. 2021 Sep 3;5(17):3387–3396. doi: 10.1182/bloodadvances.2021004511

Figure 1.

Figure 1.

PK and pharmacodynamic analyses. (A) Median serum concentration starting on cycle 1 day 1. (B) Median TO on CD14+ monocytes. (C) Median TO on CD3+ T cells. C, cycle; D, day; EOT, end of treatment; Q2W, every 2 weeks; Q3W, every 3 weeks.